Exploring Drug Delivery to the Peritoneum (1st ed. 2024)

The Peritoneal cavity (PC) is key metastatic site for intra-abdominal malignancies (e.g. GI tract and rectal cancer). PC site can be used to target several other diseases where lymphatic drug delivery is desired without dumping large amount of drug. Till recently, it was thought that treatment with curative intent was impossible but that was challenged by the introduction of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) and PIPAC (pressurized intraperitoneal aerosol chemotherapy). Recently, a growing number of preclinical and clinical studies advocate intraperitoneal (IP) chemotherapy as an alternative post-operative therapy cancer. Although their effectiveness has been proven both experimentally and clinically, there is still little understanding on role of drug delivery systems (DDS) for targeting drugs to IP cavity. Nevertheless, IP chemotherapy has not yet been adopted widely in practice for the ovarian cancer treatment, and there are several challenges in IP drug delivery.There are two main challenges one posed by IP cavity where the residence time of a small molecular weight drug (<20 kDa) is not sufficiently long to maintain therapeutic effect. This leads to frequent or continuous dosing. Another challenge is device related: catheter-related problems, such as catheter obstruction, increased risk of infection, and bowel complications. Overall literature shows that IP site is satisfactory explored by clinician but in terms of drug delivery not that much. One can see clear cut gap of expertise exchange between two fields, and guiding regulatory law makers on new medications.In summary, challenges like delivery to IP cavity, tumor or organ specific targeting, efficient tissue penetration, optimal cellular uptake and intracellular residence of a drug, biocompatibility, toxicity etc can be easily solved by smartly designing functional drug delivery systems (both nano and micro). Nanotechnologies have always fascinated human since several decades and are now widely explored in biomedical field. Diverse types of nanoparticles are being explored around the world, some examples include biodegradable nanoparticles, green nanoparticles, polymeric nanoparticles, lipid nanoparticles, metal nanoparticles, graphene, carbon nanotubes and several others. Now a day's nanoparticles are gaining interest for drug targeting of chemotherapeutic drugs, immunotherapy and gene delivery. Whereas microparticles can be explored for delayed drug delivery to peritoneal cavity due to relatively slowly removal from IP fluid. Hydrogels or other adhesive drug delivery may help to enhance peritoneal adhesions; thereby maintaining the balance between benefit-and-risk. Overall, drug delivery systems are key in IP targeting. That means drug delivery specialist and clinician needs to be connected to get best out of this route of drug administration.Present books, is a link between pharmaceutical scientist (delivery formulators), clinicians, toxicologist and regulatory experts. This book also provides new perspective to researchers to divert or guide their research in optimal way. Exploring Drug Delivery to the Peritoneum serves as a platform for upcoming technologies especially in medical devices sector to face up and show potential in delivering drug. It is a chance for commercial partners like insurance companies and pharma industry to explore in this direction.

General

Imprint:	Springer International Publishing AG
Country of origin:	Switzerland
Release date:	December 2023
First published:	2024
Editors:	Ranjita Shegokar
Dimensions:	235 x 155mm (L x W)
Pages:	480
Edition:	1st ed. 2024
ISBN-13:	978-3-03-131693-7
Categories:	Books
LSN:	3-03-131693-2
Barcode:	9783031316937

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!